Rockville, MD—U.S. retail sales of cannabis and
cannabidiol (CBD) products reached $14 billion in 2019, and are on pace
to increase 18% per year to $33 billion in 2024, according to data
published in a new report from Packaged Facts titled Cannabis and CBD: U.S. Retail Market Trends and Opportunities.
The most common delivery format for cannabis, the flower—smoked as
buds or as cigarettes—accounts for nearly 40% of retail sales, according
to a press release. Vaporizer cartridges with concentrated THC or CBD
compounds takes the second largest share, but it’s falling, as concerns
about vaping-related lung illnesses rise. Edibles and topicals are
predicted to rise, and to rise quickly, as they stand to benefit the
most from legalization of hemp-based CBD; major retailers are already
offering CBD-infused food and beverages, as well as CBD-infused
cosmetics.
The report analyzes cannabis and cannabis-related retail trends and
opportunities in the U.S., with a focus on multi-state cannabis
dispensary operators and food and beverage introductions, as well as
market trends by state. It also includes a detailed analysis of
cannabis-related legal and regulatory trends at the federal and state
levels. The report can be purchased here.
Posted by AGORACOM-JC
at 4:00 PM on Tuesday, February 25th, 2020
At a time when Cannabis stocks are struggling and in a massive state of flux, due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”.
In addition to that, Hollister has also signed LOI’s, JV’s and licensing deals with major partners with massive nationwide and even global audiences launching in the next couple of months. We’ll save details of those for another day but suffice it to say one of those partners is the world renowned Tommy Chong (of Cheech & Chong) who stated:
“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.
If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door.
BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA
Earlier today, Hollister announced an LOI to acquire Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 (subject to due diligence confirmation) … and all of that was just from the state of Arizona! Venom CEO Mason Cave and his team have aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries. Â
If you think “growth talk is cheap” (which is often the case), consider the fact that 30% of Venom’s $20,000,000 sale price kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021. In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers. It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now.
If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this interview with Hollinger President, Alex Somjen.
We loved what we heard and look forward to your feedback in Hollister’s CEO Verified Forum below!
Posted by AGORACOM-JC
at 6:10 AM on Tuesday, February 25th, 2020
Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
“Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower
VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC.(CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.
The Company has been conducting market research on advancements in
psilocybin and psychedelics in North America and globally, along with
building the business case internally on how to create greater
shareholder value, utilizing Company assets that include clinics,
patients, physicians and technology.
“There is an undeniable mental health crisis in our country and
around the world, that has an ever-increasing, devastating affect on our
society.” said Steven McAuley, Chairman & CEO of Empower. “Empower
is uniquely positioned to immediately impact research, develop new
products and bring advancements to plant-based therapies, under a
framework of rapidly increasing awareness and a movement toward
decriminalization of psychedelic treatment options.”
Studies conducted by nationally and internationally recognized
medical institutions indicate that psilocybin has shown efficacy,
tolerability, and safety in the treatment of a variety of mental health
conditions, including but not limited to addiction, depression, anxiety
disorders, and end-of-life psychological distress.
“Over the past seven years, we have assisted over one hundred
thousand patients obtain access to alternative health care and medicinal
cannabis. The provision of legal access to psilocybin therapies are
perfectly in-line with our philosophy of providing a Scientific Approach
to Alternative Medicine™“, said Dustin Klein, SVP
Business Development and Director, Empower Clinics Inc. “Clinical trials
have shown that psilocybin therapies provide tremendous help with
conditions we see everyday in our clinics. It is our responsibility, to
make sure we are providing the most up-to-date alternative therapies to
our patients and our community.”
The mental health crisis could cost the world $16 trillion by 2030
and according to Future Market Insights; the global behavioral health
(non-pharmacological) market is expected to be valued at US$156 billion
by 2028.
The United States Food and Drug Administration has determined that
preliminary clinical evidence indicates psilocybin may demonstrate
substantial improvement over other available therapies for
treatment-resistant depression; and granted a Breakthrough Therapy
designation for a treatment that uses psilocybin as a therapy for such
depression.
The Company also announces it has issued to Haywood Securities Inc.,
4,000,000 common shares of the Company (the “Work Fee Shares”) under the
financial advisory agreement dated September 25, 2019 (the “Agreement”)
based on Haywood Securities Inc. completing the final written SWOT
analysis. The shares issued are priced at fair market value of the
common shares of the Corporation as at the date of issuance of the Work
Fee Shares.
ABOUT EMPOWER
Empower is a vertically-integrated health & wellness brand with
it’s first hemp-derived CBD extraction facility under development, the
Company produces its proprietary line of cannabidiol (CBD) based
products and distributes products through company owned and franchised
clinics, with wholesale partnerships, online channels and with new
retail opportunities nationwide in the U.S. The company is a leading
multi-state operator of a network of physician-staffed wellness clinics,
focused on helping patients improve and protect their health, through
innovative physician recommended treatment options. The Company has
commenced activity on how to connect its significant data, to the
potential of the efficacy of alternative treatment options related to
hemp-derived cannabidiol (CBD) therapies, psilocybin and other
psychedelic plant-based treatment options.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
CONTACTS:
Investors: Steven McAuley Chairman & CEO [email protected] 604-789-2146
Investors: Dustin Klein SVP, Business Development [email protected] 720-352-1398
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws.
All statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release.Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to create psilocybin and
psychedelics divisions, that market research on advancements in
psilocybin and psychedelics in North America and globally will create
greater shareholder value, the Company’s intention to open a hemp-based
CBD extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the effectiveness of the extraction technology; the expected benefits
for Empower’s patient base and customers; the benefits of CBD based
products; the effect of the approval of the Farm Bill; the growth of the
Company’s patient list and that the Company will be positioned to be a
market-leading service provider for complex patient requirements in 2019
and beyond. Such statements are only projections, are based on
assumptions known to management at this time, and are subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including; that the Company may not open a
hemp-based CBD extraction facility; that legislative changes may have an
adverse effect on the Company’s business and product development; that
the Company may not be able to obtain adequate financing to pursue its
business plan; general business, economic, competitive, political and
social uncertainties; failure to obtain any necessary approvals in
connection with the proposed acquisitions and partnerships; and other
factors beyond the Company’s control. No assurance can be given that any
of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them.
Readers are cautioned not to place undue reliance on the forward-looking
statements in this release, which are qualified in their entirety by
these cautionary statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or revise any
forward-looking statements in this release, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable laws.
SOURCE: Empower Clinics Inc.
Tags: CSE, Hemp, Marijuana, small cap stocks, stocks, tsx, tsx-v Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca
Posted by AGORACOM-JC
at 6:02 AM on Tuesday, February 25th, 2020
Company signed a Letter of Intent to acquire Venom Extracts
One of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.
Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, enters into Letter of Intent to acquire Venom Extracts, one of Arizona’s largest producers of award-winning medical cannabis distillate and related products
VANCOUVER, Feb. 25, 2020 – Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a vertically integrated cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company signed a Letter of Intent (“LOI“) on February 20th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
HIGHLY ACCRETIVE $20,000,000 ACQUISITION
For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges. Hollister
cautions that revenue and EBITDA figures have not yet been audited and
are based on reports prepared by Venom management. Though Hollister believes the figures to be highly reliable, their audit will be part of the due diligence before closing.
The all stock purchase price is anticipated to be CDN$ 20,000,000, with 70% to be paid upfront and 30% to be paid upon milestone achievements. The acquisition is expected to close by March 31, 2020 subject to normal course due diligence.
“Venom has established itself as a leading extraction operation with a prominent brand in the Arizona marketplace”, said Carl Saling,
Founder and CEO of Hollister Biosciences Inc. “We feel this
acquisition will present a great deal of opportunity for synergy between
Hollister and Venom, providing avenues for both companies into the Arizona, California
and additional marketplaces for cannabis products. Venom Extracts has a
highly skilled and experienced management team with a track record for
operational excellence. This transaction is highly accretive and
represents a fundamental part of the future growth of both companies.”
LOI TERMS
The terms of the LOI, which will be formalized by a definitive agreement on closing, are as follows:
The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
The stock price will be determined based on the greater of:
The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
Once the share price is established, 70% of the Payment Shares will
be issued upon closing of the transaction, subject to hold periods.
The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).
“We are very pleased to be entering into this transaction with Hollister”, shared Mason Cave,
CEO of Venom Extracts. “The opportunities for resource and capability
sharing between the two companies are plentiful. This also represents a
more expeditious avenue for us into the large and rapidly growing California marketplace. Hollister
has an excellent management team in place and has established itself as
a sought-after brand house of popular cannabis and hemp products in
California. We feel that our contribution on the extraction side will
help diversify Hollister’s product offering and continue to
build out the brand equity of both companies across multiple state and
eventually global marketplaces”
In association with the arm’s length transaction, Hollister
will not be assuming any long-term debt, a new control position will be
created and there is no change in Management, or the Board of Directors
of Hollister being contemplated at this time.
Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a vertically integrated cannabis
company with multiple, high-quality products now carried in 220 of Indus
Holdings (CSE: INDS), Hollister’s
exclusive distribution partner’s 600 dispensaries. This level of
penetration is expected to grow as the Company accelerates its seed to
shelf, high margin business and product development model.
Capitalizing on this success, Hollister’s vision is to
become the sought-after premium brand portfolio of innovative, high
quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California,
the birthplace of the “American Biker” from which we embrace the outlaw
roots of Hollister to drive our Company fearlessly down the road of
success.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll ranked as California’s #1 hash
infused pre-roll, along with solvent-free bubble hash, pre-packaged
flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD
pet tinctures.
Venom Extracts is one of Arizona’s premier extract
brands and one of the state’s largest producers of award-winning medical
cannabis distillate and related products. With an experienced
management team and unparalleled reputation for quality, Venom Extracts
prides itself as a differentiated extraction company by producing legal
Marijuana products at a price point that allows retailers to generate
higher profits. Focused on proprietary efficiencies, the Company is
able to produce more product per square foot than its competition,
maintaining lower costs and risks than a typical extraction company. The
company’s expansion strategy is centered on entering new markets/states
that are approved for medical cannabis use and/or approved or have a
reasonable expectation to be approved for recreational use in the near
future.
Neither the Canadian Securities Exchange nor its Market Regulator
(as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile onwww.sedar.com
Tags: Cannabis, CSE, Hemp, Marijuana, stocks, tsx, tsx-v Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 4:03 PM on Monday, February 24th, 2020
In 1948, Winston Churchill said, “Those who fail to learn from history are condemned to repeat it”. Unfortunately, many Cannabis companies aren’t historians and are repeating the dot-com to dot-bomb cycle of raising tons of money but no clue how to build a real business with it.
You know what else we learned from that cycle? Web 2.0 was the birth of companies with real business plans, products, customers and revenues. They went on to dominate the next 20 years.
Enter MOTA Ventures (MOTA:CSE), who has become a leader in online CBD sales into the North American market, thanks to an e-commerce “engine” built by CEO Ryan Hoggan and his team over the past few years at Unified Funding. That engine is so powerful that is has racked up over $200 MILLION in sales from over 1 million paying customers over a number of products, including CBD sales of $25 MILLION by “First Class CBD”, which was acquired by MOTA for $32 MILLION.
The best part for MOTA shareholders? Ryan is highly motivated to continue with his successful ways because Unified Funding can earn an additional $15 MILLION if First Class CBD achieves sales of $62 MILLION. In my experience, companies don’t put bonuses into contracts unless they both believe there is a reasonable belief they can be achieved. Will he hit $62M? Or fall short at the other 2 milestones of $52M and $42M?
Watch this interview and you be the judge. Either way, MOTA shareholders should get their popcorn ready because Ryan has already proven he’s leading MOTA into the Cannabis 2.0 phase. Success is already here, now its just a question of how high MOTA will fly.
Watch this interview and share it with every investor you know!
Posted by AGORACOM-JC
at 7:34 AM on Saturday, February 22nd, 2020
Announced a transition after the definitive close of First Class CBD acquisition
Appointed Ryan Dean Hoggan to Chief Executive Officer
Acquisition of First Class CBD coupled with the upcoming U.S. roll out of the Company’s European CBD brand, Sativida, made the appointment of Mr. Hoggan to Chief Executive Officer a natural fit
Mr. Hoggan brings more than 18 years of leadership, global business development and entrepreneurship experience in the health equipment, medical devices and natural health products sectors
VANCOUVER, BC / February 22, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to announce a transition after the definitive close of First Class CBD acquisition, the Company’s Board of Directors has appointed Ryan Dean Hoggan to Chief Executive Officer. The acquisition of First Class CBD coupled with the upcoming U.S. roll out of the Company’s European CBD brand, Sativida, made the appointment of Mr. Hoggan to Chief Executive Officer a natural fit. Ryan brings a wealth of expertise to this role, being one of the founders of Unified Funding LLC and First Class CBD. Ryan is an experienced strategist, with a strong understanding of building high value consumer brands with significant annual revenue. Ryan’s extensive background in the online e-commerce space will continue to drive the Company’s rapid growth in the US and spearhead its expansion into the European market. The Company intends to continue its roll up strategy of acquiring profitable, well-known CBD brands globally.
Mr. Hoggan brings more than 18 years of leadership, global business
development and entrepreneurship experience in the health equipment,
medical devices and natural health products sectors. Early in his
career, Ryan took on a leadership role in his family business, HOGGAN
Health Industries, where he led operations, business development and
marketing efforts. After identifying an untapped niche in the market, he
founded Hoggan Medical where he went on to launch over 100 health,
fitness and medical device products and negotiated contracts with big
and small customers including the Mayo Clinic, Boeing, Daimler AG and
the Los Angeles Lakers (NBA).
In 2014, Ryan discovered the power of CBD and essential oils – both
personally and professionally – after a personal health scare prompted
him to research and subsequently try holistic products to improve his
health. The experience ultimately led him to become a Partner and
President of Offer Space, LLC and Real Oil, LLC, two rapidly growing
E-commerce and technology companies focused on serving U.S. based and
international consumers in the CBD and natural health products market.
In June 2019, Mr. Hoggan led a strategic divestiture of the businesses
to Unified Funding, LLC to help continue an impressive growth trend.
Through the operations of Unified Funding, LLC, the business has
generated a database of over 4.5 million customer records and
facilitated over $200 million in consumer transactions from more than
one million paying customers in sectors such as beauty, nutrition and
CBD products.
Mr. Hoggan holds a Bachelor of Business Administration (BBA) from
Westminster College, an MBA from The University of Arizona and a Master
of Global Management (MGM) from the Thunderbird School of Global
Management at Arizona State University.
In connection with Ryan’s appointment to CEO, Joel Shacker will
transition to the role of President of the Company and will remain a
member of the board of directors.
“I am very excited to take on the CEO role at Mota and focus the
operations on becoming a global E-commerce CBD company. I am also
excited about the partnership between Unified and Sativida. Unified’s
extensive experience in the U.S. and strong logistics and supply chain
will provide significant support for the launch of the Sativida line in
the U.S. I believe through the direct-to-consumer online platforms we
will become a leader in the CBD space. We plan to aggressively expand
First Class’s existing operations in the U.S. as well as launch a
European expansion, which we anticipate will yield similar results to
our U.S. operations last year,” stated Ryan Hoggan, CEO of the Company.
“We are extremely happy to have someone with Ryan’s extensive
experience stepping into this role. I am confident in his ability to
execute on expanding operations and generating further revenue. I look
forward to continuing to build the Company in my new role as President
and to working with Ryan during his transition to CEO of Mota.” stated
Joel Shacker.
About Mota Ventures Corp.
Mota is seeking to become a vertically integrated global CBD brand.
Its plan is to cultivate and extract CBD into high-quality value-added
products from its Latin American operations and distribute it both
domestically and internationally. Its existing operations in Colombia
consist of a 2.5-hectare site that has optimal year-round growing
conditions and access to all necessary infrastructure. Mota is looking
to establish sales channels and a distribution network internationally
through the acquisition of the Sativida and First Class CBD brands. Low
cost production, coupled with international, direct to customer sales
channels will provide the foundation for the success of Mota.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP. Joel Shacker
President
For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com
Neither the Canadian Securities Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Canadian
Securities Exchange) accepts responsibility for the adequacy or accuracy
of this press release, which has been prepared by management.
All statements in this press release, other than statements of
historical fact, are “forward-looking information” with respect to the
Company within the meaning of applicable securities laws, including with
respect to the Company’s rapid growth in the US and expansion into the
European market,its plans to become a vertically
integrated global CBD brand, its plans to cultivate and extract cannabis
to produce CBD and high-quality value added CBD products in Latin
America for distribution domestically and internationally and its plans
to acquire revenue-producing CBD brands and operations in Europe and
North America. The Company provides forward-looking statements for the
purpose of conveying information about current expectations and plans
relating to the future and readers are cautioned that such statements
may not be appropriate for other purposes. By its nature, this
information is subject to inherent risks and uncertainties that may be
general or specific and which give rise to the possibility that
expectations, forecasts, predictions, projections or conclusions will
not prove to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be achieved. These
risks and uncertainties include but are not limited those identified and
reported in the Company’s public filings under the Company’s SEDAR
profile at www.sedar.com. Although the Company has attempted to identify
important factors that could cause actual actions, events or results to
differ materially from those described in forward-looking information,
there may be other factors that cause actions, events or results not to
be as anticipated, estimated or intended. There can be no assurance that
such information will prove to be accurate as actual results and future
events could differ materially from those anticipated in such
statements. The Company disclaims any intention or obligation to update
or revise any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
SOURCE: Mota Ventures Corp.
Tags: Cannabis, CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Featured, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Announces Transition After Definitive Close of First Class #CBD Acquisition; Ryan Hoggan is New CEO $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 11:30 AM on Friday, February 21st, 2020
SPONSOR: CardioComm Solutions (EKG: TSX-V)
– The heartbeat of cardiovascular medicine and telemedicine. Patented
systems enable medical professionals, patients, and other healthcare
professionals, clinics, hospitals and call centres to access and manage
patient information in a secure and reliable environment.
M-Health Device Market is Booming Worldwide
Mhealth field has emerged as a sub-segment of eHealth, the use of information and communication technology (ICT), such as computers, mobile phones, communications satellite, patient monitors, etc., for health services and information.
According to an analyst firm, around 2.8 million patients worldwide were using a home monitoring service based on equipment with integrated connectivity
By Orian Research on February 21, 2020
According to a Latest market research report titled, ‘M-Health Device
Market’, added on Orian Research. The report has been processed on the
basis of a comprehensive analysis with inputs from industry experts. The
report presents the market scenario and its potential growth prospects
during the forecast period. The report also presents the evaluation of
the competitive landscape of the market. The leading strategies,
collaborations, innovations, and market revenue of the major players has
been elaborated in this report. The approvals and insights on the top
companies prevalent in the market will enable the reader to get
accustomed with the market opportunities that they can tackle with
informed and favorable business strategies
mHealth is an abbreviation for mobile health, a term used for the
practice of medicine and public health supported by mobile devices. The
term is most commonly used in reference to using mobile communication
devices, such as mobile phones, tablet computers and PDAs, and wearable
devices such as smart watches, for health services, information, and
data collection. The mHealth field has emerged as a sub-segment of
eHealth, the use of information and communication technology (ICT), such
as computers, mobile phones, communications satellite, patient
monitors, etc., for health services and information.
According to an analyst firm, around 2.8 million patients worldwide
were using a home monitoring service based on equipment with integrated
connectivity at the end of 2013. The figure does not include patients
that use monitoring devices connected to a PC or mobile phone. It only
includes systems that rely on monitors with integrated connectivity or
systems that use monitoring hubs with integrated cellular or fixed-line
modems.
Global M-Health Device Industry 2020 Market Research Report is spread
across 95 pages and provides exclusive vital statistics, data,
information, trends and competitive landscape details in this niche
sector.
Development policies and plans are discussed as well as manufacturing
processes and cost structures are also analyzed. This report also
states import/export consumption, supply and demand Figures, cost,
price, revenue and gross margins. The report focuses on global major
leading M-Health Device Industry players providing information such as
company profiles, product picture and specification, capacity,
production, price, cost, revenue and contact information.
The M-Health Device market report is a collection of the first-hand
data, subjective, and quantitative assessment by industry experts and
professionals, contributions from industry specialists and industry
participants over the value chain. The report consists of a detailed
analysis of the industry growth trends, micro- and macroeconomic
components, and governing factors, along with the market attractiveness,
within the market segments. The report likewise maps the subjective
impact of the different market factors on the market segments,
sub-segments, and geographies.
Major Players in M-Health Device Market are: • Allscripts • Apple • Athenahealth • Cerner • Ge Healthcare • Philips • Medtronics
This report includes the estimation of market size for value (million
USD) and volume (K Units). Both top-down and bottom-up approaches have
been used to estimate and validate the market size of M-Health Device
market, to estimate the size of various other dependent submarkets in
the overall market. Key players in the market have been identified
through secondary research, and their market shares have been determined
through primary and secondary research.
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
Posted by AGORACOM-JC
at 7:04 AM on Wednesday, February 19th, 2020
Empowers’ CBD product line Sollievo has been reformulated to include 900mg of CBD
Launched a series of re-formulated versions of it’s CBD tincture product line SOLLIEVO. Italian for Relief.
New formulated Sollievo is non-GMO, non-psychoactive, has rapid bioavailability and is sourced from USA grown hemp.
VANCOUVER BC / February 19, 2020 / EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce it has launched a series of re-formulated versions of it’s CBD tincture product line SOLLIEVO. Italian for Relief.
The new formulated Sollievo is non-GMO, non-psychoactive, has rapid
bioavailability and is sourced from USA grown hemp. The products are all
third-party lab tested for quality, and the new terpene profiles for
each of the four tincture categories of Chronic Pain, Digestion,
Insomnia and Anxiety, are aimed to promote mind and body wellness.
“We have spent the last few months dramatically increasing the
potency, flavour profiles, and profitability of the Sollievo tincture
product lines”, said Dustin Klein, SVP Business Development and
Director, Empower Clinics Inc. “Our new formulations were manufactured
in a state-of-the-art CGMP facility, ensuring quality and consistency,
and by tripling the amount of CBD per unit to 900mg, it provides a more
potent single dose to our customers, to our patients.”
The new Sollievo tincture lines are now available in the Sun Valley
Health wellness clinics, are available online and will be a standard
product offering in the Sun Valley Health franchise locations.
The Company also announces it has been awarded its 2020 Oregon
Department of Agriculture hemp handlers license, ensuring that the new
Sandy, OR extraction and production facility is compliant and licensed
to operate under the regulatory framework of the State.
“I’m excited to have our new Sollievo tinctures available for
purchase, and so proud of Dustin and our team who have brought an
exemplary product to market.” said Steven McAuley, Chairman & CEO of
Empower. “Having the hemp handlers license in place for 2020 and
continuing toward the close of our Heritage Cannabis joint venture,
allows us to control our supply chain and to bring best-in-class CBD
products to domestic and international markets.”
The Company also advises that Mat Lee’s position as CFO has concluded
and we thank Mat for his contributions. The Company continues to be
supported by Invictus Accounting and its team of specialists, who have
been integral to creating financial and accounting controls that allow
us to report quarterly results well in advance of requirements. The
Company has commenced a search for a new Chief Financial Officer.
ABOUT EMPOWER
Empower is a vertically-integrated health & wellness brand with
it’s first hemp-derived CBD extraction facility under development, the
Company produces its proprietary line of cannabidiol (CBD) based
products and distributes products through company owned and franchised
clinics, with wholesale partnerships, online channels and with new
retail opportunities nationwide in the U.S. The company is a leading
multi-state operator of a network of physician-staffed wellness clinics,
focused on helping patients improve and protect their health, through
innovative physician recommended treatment options. The company has
commenced activity on how to connect its significant data, to the
potential of the efficacy of alternative treatment options related to
hemp-derived cannabidiol (CBD) therapies.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
CONTACTS:
Investors: Steven McAuley Chairman & CEO [email protected] 604-789-2146
Investors: Dustin Klein SVP, Business Development [email protected] 720-352-1398
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws.
All statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release.Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to open a hemp-based CBD
extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the effectiveness of the extraction technology; the expected benefits
for Empower’s patient base and customers; the benefits of CBD based
products; the effect of the approval of the Farm Bill; the growth of the
Company’s patient list and that the Company will be positioned to be a
market-leading service provider for complex patient requirements in 2019
and beyond. Such statements are only projections, are based on
assumptions known to management at this time, and are subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including; that the Company may not open a
hemp-based CBD extraction facility; that legislative changes may have an
adverse effect on the Company’s business and product development; that
the Company may not be able to obtain adequate financing to pursue its
business plan; general business, economic, competitive, political and
social uncertainties; failure to obtain any necessary approvals in
connection with the proposed acquisitions and partnerships; and other
factors beyond the Company’s control. No assurance can be given that any
of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them.
Readers are cautioned not to place undue reliance on the forward-looking
statements in this release, which are qualified in their entirety by
these cautionary statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or revise any
forward-looking statements in this release, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable laws.
SOURCE: Empower Clinics Inc.
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Launches Improved Line of #CBD Products and Confirms 2020 Hemp Handlers License for Extraction Facility in Oregon $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca
Posted by AGORACOM-JC
at 2:45 PM on Friday, February 14th, 2020
SPONSOR: BetterU Education Corp.
aims to provide access to quality education from around the world. The
company plans to bridge the prevailing gap in the education and job
industry and enhance the lives of its prospective learners by developing
an integrated ecosystem. Click here for more information.
India’s EdTech industry is the second biggest in the world
India is home to the second-highest number of EdTech companies (327), followed by Brazil (275), the United Kingdom (245) and China (101).
Indian EdTech startup company BYJU’S is leading the way with the highest amount of venture capital raised.
EdTech acquisitions are on the rise with almost 200 acquisitions in the EdTech space since 2003.
RS Components has released a new report that analyses Crunchbase data, alongside a survey targeting teachers, to reveal the state of educational technology (EdTech). The report reveals the countries that are investing in EdTech the most and the EdTech companies that are leading the way.
The US has the highest number of EdTech enterprises, with 43% (1,385) of all EdTech company headquarters being based in the US.
India is home to the second-highest number of EdTech companies (327),
followed by Brazil (275), the United Kingdom (245) and China (101).
Sweden’s EdTech companies see the highest success rate in securing venture capital, with 57% of companies backed by VC funding.
Indian EdTech startup company BYJU’S is leading the way with the highest amount of venture capital raised.
EdTech acquisitions are on the rise with almost 200 acquisitions in the EdTech space since 2003.
RS Components has
analysed Crunchbase data on EdTech companies to reveal who is investing
in EdTech the most. The report looks at the countries that are home to
the most EdTech companies, as well as those that have raised the highest
capital, are receiving the most funding and have made the most
acquisitions. The full ‘State of EdTech’ report can be found here.
Which countries are leading the way in EdTech enterprises?
With a predicted market value set to reach $252 billion
in 2020, EdTech startups are on the rise all over the world. At the
heart of this surge is the US, with an overwhelming majority of 43% of
the world’s EdTech enterprises having their headquarters located in the
United States. The country’s population size, large economy, and tech
and innovation hubs, such as Silicon Valley, are likely to contribute to
its success.
India has the second-highest number of EdTech startups, with 10%
being located in the country. Brazil (9%), the UK (8%), and China (3%)
all make it into the top 5 countries leading the way in EdTech.
The countries home to the highest number of EdTech company headquarters:
Which countries are top for venture capital (VC) funding in EdTech?
When it comes to the success rates of the world’s EdTech companies in
securing funding, it’s countries like Sweden, China and Italy that come
to the fore, with over half of their EdTech startups successfully
securing funding.
Sweden leads the way, with 57% of its EdTech startups being successfully funded, and with organisations like Swedish EdTech Industry
claiming that: “Sweden will become the leading country in the world in
exploiting the opportunities and effects of digitalisation in the
education system†it’s clear that there is significant confidence in
the industry.
Sweden is also home to key initiatives in the EdTech field, such as EdTech Sweden
– an annual event, hosted in Stockholm, that is a combination of a
conference, exhibition and a networking event where experts in the field
share and discuss best practices and new digital solutions that promote
learning.
The countries where the highest proportion of EdTech companies are securing funding:
Where are EdTech companies receiving the most funding?
Just under one third (31%) of EdTech companies have successfully
attracted VC funding, with 1,019 enterprises in the industry attracting a
total of $14 billion. When it comes to the average amount of funding
each EdTech company attracts, China is where companies come out on top,
with an average of $43.9 million being invested into individual EdTech
companies.
Luxembourg is a close second, with EdTech companies here attracting
an average investment of $35.4 million each. Compare this with the US,
home to the most EdTech companies where each attracts an average of
$16.6 million, and it’s clear that countries like China and Luxembourg
are putting a much higher value on EdTech.
Which EdTech companies are leading the way?
India is home to the EdTech startup, BYJU’s, which has raised the highest amount of capital, at $969 million. Following shortly behind are China’s Yuanfudao at $544m and Zhangmen at $499m.
Seven of the highest funded companies are based in the US, with the
likes of Coursera, Laureate Education and 2U Inc. attracting a total of
$313.1 million, $400 million and $426.8 million, respectively.
Have EdTech acquisitions increased?
According to Crunchbase, there have been almost 200 acquisitions in
the EdTech space since 2003. While few were made between 2003 and 2009,
acquisitions have been on a steady rise since the early 2010s, with 37
acquisitions in 2018, 36 in 2017 and 33 in 2016.
The most notable acquisition in the space was LinkedIn’s $1.5 billion
purchase of Lynda in 2015. The company, now known as LinkedIn Learning,
is a provider of online video courses taught by industry experts in
software, creative, and business skills.
A spokesperson from RS Components comments:
“EdTech is clearly seeing a huge boom at the moment, with
acquisitions on the rise and its market value set to hit $252 billion
this year, so it’s great to see tech entrepreneurs all over the world
bringing their talents to the industry.
“With more than 40% of EdTech companies setting up their headquarters
in the US, it looks like the country is becoming a hub for EdTech
startups. However, with companies in China and Luxembourg receiving the
highest proportion of funding and the likes of Sweden, Italy and Austria
being home to the most companies that are successfully securing
funding, it’s clear that there are opportunities for EdTech startups all
over the world.â€
Posted by AGORACOM-JC
at 1:00 PM on Friday, February 14th, 2020
SPONSOR: Datametrex AI Limited
(TSX-V: DM) A revenue generating small cap A.I. company that NATO and
Canadian Defence are using to fight fake news & social media
threats. The company announced three $1M contacts in Q3-2019. Click here for more info.
Deepfakes and deep media: A new security battleground
In anticipation of this new reality, a coalition of academic institutions, tech firms, and nonprofits are developing ways to spot misleading AI-generated media
Their work suggests that detection tools are a viable short-term solution but that the deepfake arms race is just beginning
Deepfakes — media that takes a person in an existing image, audio
recording, or video and replaces them with someone else’s likeness using
AI — are multiplying quickly. That’s troubling not only because these
fakes might be used to sway opinions during an election or implicate a
person in a crime, but because they’ve already been abused to generate pornographic material of actors and defraud a major energy producer.
In anticipation of this new reality, a coalition of academic
institutions, tech firms, and nonprofits are developing ways to spot
misleading AI-generated media. Their work suggests that detection tools
are a viable short-term solution but that the deepfake arms race is just
beginning.
Deepfake text
The best AI-produced prose used to be closer to Mad Libs than The Grapes of Wrath, but cutting-edge language models can now write with humanlike pith and cogency. San Francisco research firm OpenAI’s GPT-2 takes seconds to craft passages in the style of a New Yorkerarticle or brainstorm game scenarios. Of greater concern, researchers
at Middlebury Institute of International Studies’ Center on Terrorism,
Extremism, and Counterterrorism (CTEC) hypothesize that GPT-2 and others
like it could be tuned to propagate white supremacy, jihadist Islamism,
and other threatening ideologies.
Above: The frontend for GPT-2, AI research firm OpenAI’s trained language model.Image Credit: OpenAI
In pursuit of a system that can detect synthetic content, researchers
at the University of Washington’s Paul G. Allen School of Computer
Science and Engineering and the Allen Institute for Artificial
Intelligence developed Grover,
an algorithm they claim was able to pick out 92% of deepfake-written
works on a test set compiled from the open source Common Crawl corpus.
The team attributes its success to Grover’s copywriting approach, which
they say helped familiarize it with the artifacts and quirks of
AI-originated language.
A team of scientists hailing from Harvard and the MIT-IBM Watson AI Lab separately released The Giant Language Model Test Room,
a web environment that seeks to determine whether text was written by
an AI model. Given a semantic context, it predicts which words are most
likely to appear in a sentence, essentially writing its own text. If
words in a sample being evaluated match the top 10, 100, or 1,000
predicted words, an indicator turns green, yellow, or red, respectively.
In effect, it uses its own predictive text as a benchmark for spotting
artificially generated content.
Deepfake videos
State-of-the-art video-generating AI is just as capable (and dangerous) as its natural language counterpart, if not more so. An academic paper
published by Hong Kong-based startup SenseTime, the Nanyang
Technological University, and the Chinese Academy of Sciences’ Institute
of Automation details a framework that edits footage by using audio to
synthesize realistic videos. And researchers at Seoul-based Hyperconnect
recently developed a tool — MarioNETte
— that can manipulate the facial features of a historical figure,
politician, or CEO by synthesizing a reenacted face animated by the
movements of another person.
Even the most realistic deepfakes contain artifacts that give them
away, however. “Deepfakes [produced by] generative [systems] learn a
data set of actual images in videos, to which you add new images and
then generate a new video with the new images,†Ishai Rosenberg, head of
the deep learning group at cybersecurity company Deep Instinct, told
VentureBeat via email. “The result is that the output video has subtle
differences because there are changes in the distribution of the data
that is generated artificially by the deepfake and the distribution of
the data in the original source video. These differences, which can be
referred to as ‘glimpses in the matrix,’ are what the deepfake detectors
are able to distinguish.â€
Above: Two deepfake videos produced using state-of-the-art methods.Image Credit: SenseTime
Last summer, a team from the University of California, Berkeley and the University of Southern California trained a model
to look for precise “facial action units†— data points of people’s
facial movements, tics, and expressions, including when they raise their
upper lips and how their heads rotate when they frown — to identify
manipulated videos with greater than 90% accuracy. Similarly, in August
2018 members of the Media Forensics program at the U.S. Defense Advanced
Research Projects Agency (DARPA) tested systems that could detect AI-generated videos from cues like unnatural blinking, strange head movements, odd eye color, and more.
Several startups are in the process of commercializing comparable deepfake video detection tools. Amsterdam-based Deeptrace Labs
offers a suite of monitoring products that purport to classify
deepfakes uploaded on social media, video hosting platforms, and
disinformation networks. Dessa has proposed techniques for improving deepfake detectors trained on data sets of manipulated videos. And Truepic raised an $8 million funding round in July 2018
for its video and photo deepfake detection services. In December 2018,
the company acquired another deepfake “detection-as-a-service†startup —
Fourandsix — whose fake image detector was licensed by DARPA.
Above: Deepfake images generated by an AI system.
Beyond developing fully trained systems, a number of companies have
published corpora in the hopes that the research community will pioneer
new detection methods. To accelerate such efforts, Facebook — along with
Amazon Web Services (AWS), the Partnership on AI, and academics from a
number of universities — is spearheading the Deepfake Detection
Challenge. The Challenge includes a data set of video samples labeled to
indicate which were manipulated with AI. In September 2019, Google
released a collection
of visual deepfakes as part of the FaceForensics benchmark, which was
cocreated by the Technical University of Munich and the University
Federico II of Naples. More recently, researchers from SenseTime
partnered with Nanyang Technological University in Singapore to design DeeperForensics-1.0, a data set for face forgery detection that they claim is the largest of its kind.
Deepfake audio
AI and machine learning aren’t suited just to video and text synthesis — they can clone voices, too. Countlessstudies
have demonstrated that a small data set is all that’s required to
recreate the prosody of a person’s speech. Commercial systems like those
of Resemble
and Lyrebird need only minutes of audio samples, while sophisticated
models like Baidu’s latest Deep Voice implementation can copy a voice
from a 3.7-second sample.
Deepfake audio detection tools are not yet abundant, but solutions are beginning to emerge.
Several months ago, the Resemble team released an open source tool dubbed Resemblyzer,
which uses AI and machine learning to detect deepfakes by deriving
high-level representations of voice samples and predicting whether
they’re real or generated. Given an audio file of speech, it creates a
mathematical representation summarizing the characteristics of the
recorded voice. This enables developers to compare the similarity of two
voices or suss out who’s speaking at any given moment.
In January 2019, as part of its Google News Initiative, Google
released a corpus of speech containing “thousands†of phrases spoken by
the company’s text-to-speech models. The samples were drawn from English
articles spoken by 68 different synthetic voices and covered a variety
of regional accents. The corpus is available to all participants of ASVspoof 2019, a competition that aims to foster countermeasures against spoofed speech.
A lot to lose
No detector has achieved perfect accuracy, and researchers haven’t
yet figured out how to determine deepfake authorship. Deep Instinct’s
Rosenberg anticipates this is emboldening bad actors intent on
distributing deepfakes. “Even if a malicious actor had their [deepfake]
caught, only the [deepfake] itself holds the risk of being busted,†he
said. “There is minimal risk to the actor of getting caught. Because the
risk is low, there is little deterrence to creating deepfake[s].â€
Rosenberg’s theory is supported by a report
from Deeptrace, which found 14,698 deepfake videos online during its
most recent tally in June and July 2019 — an 84% increase within a
seven-month period. The vast majority of those (96%) consist of
pornographic content featuring women.
Considering those numbers, Rosenberg argues that companies with “a
lot to lose†from deepfakes should develop and incorporate deepfake
detection technology — which he considers akin to antimalware and
antivirus — into their products. There’s been movement on this front;
Facebook announced
in early January that it will use a combination of automated and manual
systems to detect deepfake content, and Twitter recently proposed flagging deepfakes and removing those that threaten harm.
Of course, the technologies underlying deepfake generators are merely
tools — and they have enormous potential for good. Michael Clauser,
head of the data and trust practice at consultancy Access Partnership,
points out that the technology has already been used to improve medical
diagnoses and cancer detection, fill gaps in mapping the universe, and
better train autonomous driving systems. He therefore cautions against
blanket campaigns to block generative AI.
“As leaders begin to apply existing legal principles like slander and
defamation to emerging deepfake use cases, it’s important not to throw
out the baby with the bathwater,†Clauser told VentureBeat via email.
“Ultimately, the case law and social norms around the use of this
emerging technology [haven’t] matured sufficiently to create bright red
lines on what constitutes fair use versus misuse.â€